Drugs / alizapride
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01636947 Background | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alizapride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01636947 ↗ |
| Known as | Alizaprida | ChEMBL registry synonym — accepted as the source's own label CHEMBL290194 ↗ |
| Known as | Litican | ChEMBL registry synonym — accepted as the source's own label CHEMBL290194 ↗ |
| Known as | Plitican | ChEMBL registry synonym — accepted as the source's own label CHEMBL290194 ↗ |
| Known as | Superan | ChEMBL registry synonym — accepted as the source's own label CHEMBL290194 ↗ |
| Known as | Vergentan | ChEMBL registry synonym — accepted as the source's own label CHEMBL290194 ↗ |
| Action | Inhibit | “Dopamine D2 receptor antagonist” CHEMBL290194 ↗ |
| Modality | Small molecule | — CHEMBL290194 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL290194 ↗ |